CDT Conduit Pharmaceuticals Inc. - 8-K

EX-99.1
2
ex99-1.htm
EX-99.1

Exhibit
99.1

CDT
Equity Inc. Announces Receipt of Nasdaq Deficiency Letter

NAPLES,
Fla. and CAMBRIDGE, United Kingdom, May 28, 2026 (GLOBE NEWSWIRE) - CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”),
today announced that the Company received a written notice (“Notice”) from the Nasdaq Listing Qualifications Department of
The Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2026 indicating that the Company did not timely file its Quarterly Report
on Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”), as required for continued listing on The
Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”). The Notice does not
have an immediate effect on the listing or trading of the Company’s securities. The Notice provided that under Nasdaq rules, the
Company has until July 20, 2026 to submit a plan to regain compliance with the Periodic Filing Requirement. The Company anticipates filing
its Form 10-Q as soon as the review process of the current draft is complete, thereby regaining compliance with the Periodic Filing Requirement.

About
CDT Equity Inc.

CDT
Equity Inc. (Nasdaq: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential
therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company
has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning
to accelerate the development of novel treatments. Looking ahead, CDT is committed to creating shareholder value through licensing, strategic
M&A, and positioning the company as a platform for transformative innovation.

Cautionary
Statement Regarding Forward-Looking Statements

This
press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than
statements of historical facts contained in this press release, including statements regarding CDT’s future results of operations
and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development costs,
timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated
studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking
statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,”
“plan,” “may,” “should,” “will,” “would,” “will be,” “will
continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number
of risks, uncertainties and assumptions, including, but not limited to: the effect that the Notice may have on the Company’s securities;
the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits
of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the
combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates
in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a
timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic,
business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities
and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements
are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s
control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by
law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information,
future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors

CDT
Equity Inc.

[email protected]